Login / Signup

Gonadotropin-Releasing Hormone Agonist Versus Recombinant Human Chorionic Gonadotropin Triggering in Fertility Preservation Cycles.

Einat Haikin HerzbergerSabaa KnanehHadar AmirAdi RechesDalit Ben-YosefYael KalmaFoad AzemNivin Samara
Published in: Reproductive sciences (Thousand Oaks, Calif.) (2021)
The purpose of this research is to study the efficacy of GnRH-a versus r-hCG triggering in patients who go through fertility preservation cycles. This retrospective cohort study was performed in a tertiary university-affiliated medical center. It includes 191 patients undergoing fertility preservation cycles between May 2013 and September 2018, in which ovulation was induced by either GnRH-a or r-hCG. Main outcome measures were number and rate of mature oocyte. Among treatment cycles with medical indication, GnRH agonist significantly increases the odds for high mature rate by 3.55 (1.30-9.66), while in treatment cycles with social indication, there is no significant effect of the triggering agent. An advantage for GnRH-a triggering was observed in medically indicated preservation cycles.
Keyphrases
  • patients undergoing
  • recombinant human
  • healthcare
  • metabolic syndrome
  • adipose tissue
  • type diabetes
  • polycystic ovary syndrome
  • replacement therapy